MARKET

GENB

GENB

Generate Biomedicines
NASDAQ
14.53
+0.55
+3.93%
After Hours: 14.54 +0.01 +0.07% 19:44 05/22 EDT
OPEN
14.37
PREV CLOSE
13.98
HIGH
15.21
LOW
14.35
VOLUME
784.85K
TURNOVER
--
52 WEEK HIGH
16.75
52 WEEK LOW
11.00
MARKET CAP
1.86B
P/E (TTM)
-7.4216
1D
5D
1M
3M
1Y
5Y
1D
Can Nvidia’s Backing Reframe Generate Biomedicines (GENB) as a Scaled AI Drug Developer?
Simply Wall St · 1d ago
A Look At Generate Biomedicines (GENB) Valuation After Nvidia’s US$10.4 Million Investment
Simply Wall St · 3d ago
This AI Biotech Stock Landed a $10.4 Million Nvidia Investment
Barchart · 5d ago
Weekly Report: what happened at GENB last week (0511-0515)?
Weekly Report · 05/18 10:51
NVIDIA Corporation Increases Stake In CoreWeave To 47,213,353 Shares, Maintains Holdings In Intel Corporation (214,776,632 Shares), Nebius Group N.V. (1,190,476 Shares), Nokia Corporation (166,389,351 Shares), Synopsys (4,821,717 Shares), Takes New Stakes In Coherent Corp. (7,788,161 Shares) Generate Biomedicines (833,325 Shares).
Benzinga · 05/15 20:24
Nvidia Takes New Stake In Generate Biomedicines With 833,325 Shares
Benzinga · 05/15 20:19
Generate Biomedicines Price Target Raised to $22.00/Share From $20.00 by Morgan Stanley
Dow Jones · 05/14 17:25
Generate Biomedicines Is Maintained at Overweight by Morgan Stanley
Dow Jones · 05/14 17:25
More
About GENB
Generate Biomedicines, Inc. is a clinical-stage generative biology company focusing on the Artificial intelligence (AI) revolution in biotechnology and drug design and development. The Company is engaged in the field of generative biology using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its Generate Platform integrates generative and predictive models that learn design principles from proprietary data and graph neural networks, among other architectures. Its lead product candidate, GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma. Its other product candidates include GB-4362, a systemically administered monoclonal antibody designed to neutralize free monomethyl auristatin E (MMAE) as an adjunctive therapy to antibody-drug conjugate (ADC) molecules with an MMAE payload, as well as GB-5267, an armored, MUC16-directed CAR-T cell therapy candidate.

Webull offers Generate Biomedicines Inc stock information, including NASDAQ: GENB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GENB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GENB stock methods without spending real money on the virtual paper trading platform.